Table 2.
Studies Investigating Neutrophil ROS production in Diabetes.
| Study | Animal model/human volunteer type | Changes in neutrophil ROS production reported in diabetes group compared to healthy control |
|---|---|---|
| Studies investigating neutrophil extracellular ROS production | ||
| (54) | HVs + people with T2D | ↑ in response to PMA and zymosan |
| (136) | HVs + people with T2D | ↑ in response to PMA ↓ in response to zymosan |
| (137) | HVs + PWD (does not specify type) | No difference in response to PMA |
| (138) | HVs + people with T1D | ↑ in unstimulated neutrophils. ↓ in response to fMLP and no difference when using PMA |
| (55) | Akita mouse (point mutation in Ins2 gene- inability to produce insulin-T1D model) | ↑ in response to fMLP |
| (139) | HVs+ well controlled T1D | No difference in response to PMA |
| (140) | HVs+ volunteers with poor, moderate or well controlled T1D or T2D | ↑ in response to fMLP in poorly controlled diabetes only (>8% HbA1c) |
| (123) | Low dose STZ-treated mice vs. WT | ↓ in response to PMA |
| (141) | Healthy cats vs. diabetic cats (partial pancreatectomy) | ↑ in response to PMA |
| (142) | HVs + patients with diabetes (T1D or T2D) | ↑ in unstimulated neutrophils but decreased in response to PMA and zymosan |
| (143) | HVs + people with poorly controlled T2D | ↓ in response to a mixture of zymosan, phorbol and NaF |
| (144) | HVs + patients with odontogenic bacterial infections or oral candidiasis with or without diabetes | ↓ in response to PMA |
| (59) | HVs+ people with T1D or T2D with and without varying severities of periodontitis | ↑ ROS in response to PMA and fMLP in participants with moderate (7-8%) or poor (>8%) glucose control |
| (145) | HVs + people with DFD | ↓ in ROS in response fMLP. G-CSF increased ROS. |
| Studies investigating neutrophil intracellular ROS production | ||
| (122) | HVs + people with T2D undergoing tooth extractions | ↓ in ROS (stimulus not reported) |
| (146) | HVs + people with T2D and varying stages of diabetic nephropathy | ↑ ROS. Greatest increase in patients with stage 4 nephropathy. (Multiple stimuli employed) |
| (147) | Newly diagnosed T1D patients not yet undergoing insulin therapy, T1D patients with disease duration of >3 months and healthy controls | ↓ in ROS in response to PMA (greatest decrease in patients without insulin therapy) |
| (148) | HVs + people with T1D or T2D | ↓ in ROS in response to PMA. Tolrestat increased ROS |
| (149) | HVs + infection free people with poorly controlled T2D (HbA1C <7.5%) | ↓ in ROS in response to PMA |
| (126) | HVs + people with T2D and periodontitis | No difference in response to PMA. ↓ in response to zymosan |
| (150) | STZ-treated rats v.s WT rats | ↑ ROS at basal level (no stimulus used) |
| (125) | HVs + people with diabetes and periodontal disease | No difference in response to PMA. ↓ in response to zymosan |
| (49) | HVs + People with T1D or T2D | No difference in response to PMA |
| (151) | HVs + people with T1D or T2D | ↓ in response to endotoxin activated plasma |
| (141) | Healthy cats & diabetic cats (partial pancreatectomy) | No difference in response to PMA |
| Studies investigating neutrophil intracellular and extracellular ROS production using chemiluminescence | ||
| (142) | HVs + patients with diabetes (T1D and T2D) | ↑ in unstimulated neutrophils but decreased in response to PMA and zymosan |
| (152) | HVs + people with T2D | ↓ in response to PMA |
| (153) | WT Wistar rats v.s STZ treated rats | ↓ in response to fMLP |
| (154) | HVs + people with T1D or T2D | ↓ in response to PMA |
| (155) | WT Fisher Rats + STZ treated rats | ↑ in response to bradykinin |
| (143) | WT Wistar rats v.s STZ treated rats | ↓ in response to opsonised zymosan |
| (151) | HVs + people with T1D or T2D | ↑ in response to opsonised zymosan |
| (156) | HVs + people with T2D | ↓ in response to fMLP |
| (157) | HVs + people with T1D and T2D | ↑ ROS in response to cAMP-elevating agent- dibutyryl cAMP |
| (158) | Healthy wistar rats v.s alloxan treated rats | ↑ ROS in response to PMA |
| (159) | HVs + people with T2D | ↑ ROS at rest and in response to PMA |
| (49) | HVs + people with T1D or T2D | ↓ ROS in response to opsonised zymosan and PMA |
| (160) | HVs+ poorly controlled T1D patients | ↓ ROS in response to PMA |
HVs, Healthy volunteers; fMLP, N-Formyl-methionyl-leucyl-phenylalanine; cAMP, cyclic adenosine monophosphate; NaF, Neutrophil activating factor; WT, Wild-type; G-CSF, Granulocyte colony stimulating factor.